Honeywell Aerospace faces securities probe after 23% stock plunge

Shares of Honeywell Aerospace plunged 23.16% on Aug. 6 after Q2 results missed estimates, prompting Hagens Berman to open a securities investigation into potential false or misleading statements.

"Our investigation focuses on whether Honeywell Aerospace downplayed ongoing supply chain constraints and manufacturing vulnerabilities during its June Investor Day while assuring investors that operational hurdles were already being resolved," Reed Kathrein, the Hagens Berman partner leading the firm's investigation, said.

The probe centers on statements made at the June 3 Investor Day in Scottsdale, Arizona, just weeks before the company's spin-off from Honeywell International on June 29. CEO Jim Currier and CFO Josh Jepsen targeted at least $6.5 billion in earnings and $4 billion in cash flow by 2030. Management acknowledged an "acute issue" in the first quarter but assured investors that supply chain improvements were underway and that mitigation efforts had begun resolving bottlenecks in March, with the company "doubling down and tripling down on manufacturing scale" to handle demand.

On Aug. 5, the company reported its first standalone Q2 results — a significant top- and bottom-line miss — and cut full-year organic growth guidance to 4%-5% from 7%-9%. Management blamed persistent mechanical supply chain bottlenecks that forced the company to prioritize lower-margin original equipment deliveries over highly profitable aftermarket sales, effectively "resetting" its near-term growth trajectory. The bottlenecks forced the company to defer aftermarket orders, which carry significantly higher margins, to keep up with OE commitments.

The stock closed at $156.47 on Aug. 6, down from a 12-month high of $297.50, giving the company a market capitalization of $51.09 billion and a P/E ratio of 86.20. Analysts have responded with a wave of target cuts: BMO Capital Markets lowered its target to $209 from $276, Royal Bank of Canada cut to $250 from $300, and BNP Paribas Exane trimmed to $210 from $245. Morgan Stanley upgraded the stock to overweight with a $205 target. The consensus rating stands at Hold with an average price target of $224.17.

Institutional investors have been establishing new positions despite the turmoil. Cullen Capital Management acquired 106,610 shares worth approximately $23.6 million in the second quarter, while Grandfield & Dodd, SCS Capital Management, SFE Investment Counsel, and MidFirst Bank also bought new stakes. The investigation could lead to additional shareholder litigation and SEC scrutiny, with whistleblowers potentially eligible for rewards of up to 30 percent of any successful recovery.

The investigation adds legal risk on top of operational headwinds, potentially extending the stock's decline. Investors will watch for any SEC enforcement action or additional shareholder lawsuits, while the company's next earnings report will test whether supply chain issues are truly resolved.

This article is for informational purposes only and does not constitute investment advice.